On August 30, 2018 Personalis, Inc., a leading provider of advanced genomic sequencing and analytics to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies, reported that they are scheduled to present at the Immuno-Oncology Summit in Boston, MA on August 30, 2018 at 12:15 PM ET (Press release, Personalis, AUG 30, 2018, View Source [SID1234529174]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, entitled "Overcoming the Obstacles of Neoantigen Detection for Cancer Vaccine Development," will discuss how the Personalis ACE ImmunoID Platform addresses the challenges associated with accurately identifying candidate neoantigens to enable the development of safe and efficacious personalized cancer vaccines. The presentation will be delivered by Kedar Hastak, PhD, Field Applications Scientist.

ACE ImmunoID is a universal immunogenomics platform, purpose-built for precision oncology applications, combining highly-sensitive exome and transcriptome sequencing with advanced analytics. The platform provides a multidimensional view of both the tumor and its microenvironment, and is the platform-of-choice for many industry-leading biopharma in the neoantigen-based cancer immunotherapy field.